|
||||||
|
Datasets with Breast_cancer |
 The duplicated datasets indicate that this dataset include both pre-treatment and post-treatment samples, and partial analyses were conducted on each of the two timepoints. The dataset page shows more informations, and the analysis results of this dataset. |
| Dataset | Source | Tissue | Cancer type level1 | Cancer type level2 | Drug type | Regimen | Timepoint |
GSE163836 | FCIBC02 cell line | Cell line | Breast cancer | Inflammatory breast cancer | Chemotherapy | paclitaxel | NA |
GSE169246_PacTissue | patients | Tumor tissue | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel | post |
GSE169246_PacTissue | patients | Tumor tissue | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel | pre |
GSE131984_Pac | SUM159 cell line | Cell line | Breast cancer | Triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel | NA |
GSE169246_PacBlood | patients | Peripheral blood mononuclear cells | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel | post |
GSE169246_PacBlood | patients | Peripheral blood mononuclear cells | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel | pre |
GSE169246_PacAteBlood | patients | Peripheral blood mononuclear cells | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Immunotherapy | atezolizumab + paclitaxel | post |
GSE169246_PacAteBlood | patients | Peripheral blood mononuclear cells | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Immunotherapy | atezolizumab + paclitaxel | pre |
GSE169246_PacAteTissue | patients | Tumor tissue | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Immunotherapy | atezolizumab + paclitaxel | post |
GSE169246_PacAteTissue | patients | Tumor tissue | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Immunotherapy | atezolizumab + paclitaxel | pre |
GSE104987 | MCF7 cell line | Cell line | Breast cancer | ER+ breast cancer | Targeted therapy | KDM5-C70 | NA |
GSE131984_JQ1 | SUM159 cell line | Cell line | Breast cancer | Triple-negative breast cancer (TNBC) | Targeted therapy | JQ1 | NA |
GSE131984_JQ1Pal | SUM159 cell line | Cell line | Breast cancer | Triple-negative breast cancer (TNBC) | Targeted therapy | JQ1 + palbociclib | NA |
GSE131984_JQ1Pac | SUM159 cell line | Cell line | Breast cancer | Triple-negative breast cancer (TNBC) | Targeted therapy | JQ1 + paclitaxel | NA |
GSE131984_Pal | SUM159 cell line | Cell line | Breast cancer | Triple-negative breast cancer (TNBC) | Targeted therapy | palbociclib | NA |
Copyright 2022-Present -The University of Texas Health Science Center at Houston |